IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill could help ITP patients who failed other treatments
Disease control Recruiting nowThis study tests a drug called pirtobrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The trial has two parts: first, finding safe doses, then comparing pirtobrutinib to a placebo to see if it ra…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for teens with rare bleeding disorder: experimental drug enters final testing
Disease control Recruiting nowThis study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug mimics IVIg to fight low platelet disorder
Disease control Recruiting nowThis study tests a new drug called NVG-2089 in 30 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The drug is designed to work like IVIg, calming the immune system. Researchers will check for side effects …
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Nuvig Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug targets immune overdrive in six rare diseases
Disease control Recruiting nowThis early-stage trial is testing a drug called RAY121 in 144 people with one of six immune diseases, including antiphospholipid syndrome and bullous pemphigoid. The drug works by blocking a specific part of the immune system (the complement pathway) that can cause tissue damage.…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New antibody drug aims to boost platelets in Hard-to-Treat ITP
Disease control Recruiting nowThis early-phase trial is testing a new drug called budoprutug (TNT119) in 24 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive two IV doses and are monitored for safety, how the drug mov…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1, PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill could help ITP patients who failed standard treatments
Disease control Recruiting nowThis phase 2 trial tests an experimental oral drug called DZD8586 (Birelentinib) in adults with primary immune thrombocytopenia (ITP) whose condition did not improve after at least one standard therapy. About 60 participants will receive one of three dose levels to see if it safe…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New IVIG treatment aims to boost platelets in bleeding disorder
Disease control Recruiting nowThis study tests whether V-IMMUNE, a human immunoglobulin given through a vein, can safely raise platelet counts in people with immune thrombocytopenia (ITP). About 31 adults and children aged 1 year and older with very low platelets will receive two daily infusions. The main goa…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New antibody therapy targets stubborn autoimmune blood diseases
Disease control Recruiting nowThis study tests an experimental drug called CM336 in people with relapsed or refractory autoimmune cytopenia, including ITP and autoimmune hemolytic anemia. CM336 is a bispecific antibody designed to target and eliminate certain immune cells. The trial will enroll 158 adults to …
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1, PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Immune reset: CAR-T therapy takes on lupus, myositis, and ITP
Disease control Recruiting nowThis early-phase study tests a new cell therapy called BZE2204 in 20 people with lupus, myositis, or immune thrombocytopenia (ITP) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune syste…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:04 UTC
-
Could a multiple sclerosis drug help treat a bleeding disorder?
Disease control Recruiting nowThis study tests whether adding teriflunomide (a drug used for multiple sclerosis) to standard high-dose dexamethasone works better than dexamethasone alone for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, caus…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:37 UTC